Centessa Pharmaceuticals plc, together with its subsidiaries, discovers develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2 Idiopathic hypersomnia, as well as the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders.
Its portfolio also includes ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders, and LockBody, an early-stage immuno-oncology program technology platform. Incorporated in 2020, the company is headquartered in Altrincham, the United Kingdom.
Key Stats
BetaN/A
Trailing P/EN/A
Forward P/EN/A
Trailing EPSN/A
Avg VolumeN/A
Enterprise ValueN/A
Shares Outstanding
Earnings & Analyst
Next EarningsN/A
EPS EstimateN/A
Target Mean PriceN/A
RecommendationN/A
Recommendation MeanN/A
Recent SEC Filings
SEC filings for this ticker are not available yet.
Frequently Asked Questions
What does Centessa Pharmaceuticals (CNTA) do?
Centessa Pharmaceuticals plc is a biotechnology company focused on discovering, developing, and delivering orexin-based neuroscience therapeutics. Its lead product candidate is ORX750, an orexin receptor 2 agonist currently in Phase IIa clinical trials for central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. The company also has ORX142, a Phase I candidate for neurological and neurodegenerative disorders, and ORX489, a Phase I candidate for neuropsychiatric disorders. Additionally, Centessa is developing LockBody, an early-stage immuno-oncology platform technology. The company operates primarily in the United Kingdom and the United States.
Where is Centessa Pharmaceuticals (CNTA) listed and in which currency?
Centessa Pharmaceuticals plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CNTA. Its shares are traded in US dollars (USD), reflecting its primary listing on a US exchange. The company is headquartered in Altrincham, United Kingdom, but its listing on NasdaqGS provides access to global investors, particularly in the US market.
What sector and industry does Centessa Pharmaceuticals (CNTA) belong to?
Centessa Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Centessa focus on using biological processes to develop therapies and drugs. In Centessa's case, its core expertise lies in orexin-based neuroscience therapeutics, targeting conditions such as narcolepsy, hypersomnia, and neurodegenerative disorders. The company's pipeline includes both clinical-stage and early-stage programs, reflecting the high-risk, high-reward nature of the biotech industry.
Where is Centessa Pharmaceuticals (CNTA) headquartered and what markets does it serve?
Centessa Pharmaceuticals plc is headquartered in Altrincham, United Kingdom. The company operates in both the United Kingdom and the United States, as indicated by its discovery and development activities. Its clinical trials for products like ORX750, ORX142, and ORX489 are likely conducted in these regions. While the company's primary market focus is on neuroscience therapeutics, its immuno-oncology platform LockBody suggests potential expansion into oncology. The company serves patients and healthcare providers in the UK and US, with a global reach through its Nasdaq listing.
What is the business model of Centessa Pharmaceuticals (CNTA) and how does it generate revenue?
Centessa Pharmaceuticals is a clinical-stage biotechnology company that generates revenue primarily through the development and potential commercialization of its proprietary therapeutics. As of the available data, the company does not have any approved products on the market; its pipeline includes ORX750 (Phase IIa), ORX142 (Phase I), and ORX489 (Phase I), as well as the early-stage LockBody platform. Revenue, if any, may come from research collaborations, grants, or licensing agreements, but the company's main focus is on advancing its candidates through clinical trials to achieve regulatory approval. Once approved, Centessa would generate revenue from sales of its therapies in the neuroscience and immuno-oncology fields.